Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 328Lung Neoplasms 158Pancreatic Neoplasms 30Adenocarcinoma of Lung 27Colorectal Neoplasms 26Neoplasms 24Small Cell Lung Carcinoma 21Breast Neoplasms 17Neoplasm Metastasis 15Mesothelioma, Malignant 14Ovarian Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Mesothelioma 10Stomach Neoplasms 9Colonic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Sarcoma 7Prostatic Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Melanoma 6Lymphoma, Non-Hodgkin 6Esophageal Neoplasms 6Lymphoma 5Thoracic Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4

Interventions

Pemetrexed 2Carboplatin 2durvalumab 1Tretinoin 1Surgical Procedures, Operative 1Paclitaxel 1Observation 1Gemcitabine 1Cisplatin 1Bortezomib 1Azacitidine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Gemcitabine × Thoracic × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡